Introduction Pre-treatment measurement of red blood cell (RBC) thiopurine-S-methyltransferase (TPMT) activity is recommended to guide initial dosing of azathioprine (AZA) and mercaptopurine (MP). TPMT exhibits a trimodal distribution, with low and intermediate activities predicting myelotoxicity at standard drug doses. There is a high concordance between TPMT genotype and normal or low enzyme activity (93–100%); however the relationship is poor in the intermediate range (53–100%) . Furthermore, there are few explanations for the wide variation in inter-individual TPMT activities in the wild-type range. Bioavailability of the cofactor S-adenosylmethionine (SAM) and RBC age may play a role. The aim of this study was to determine if gender or anaemia influences RBC TPMT activity.
Methods We analysed a retrospective cohort of 6,496 RBC TPMT samples (n = 3804 females, n = 2692 males) measured in the PRL since 2004 and correlated enzyme activity with gender and haemoglobin concentrations.
Results A greater portion of females exhibited intermediate TPMT activity (13.46%) as compared to males (11.07%). The mean TPMT activity was also significantly lower in females (32.94 pmol/mg Hb/h) versus males (34.13 pmol/mg Hb/h; p = < 0.0001, 95% CI 0.7950–1.589). When separated by low, intermediate or normal TPMT activity, this relationship only remained in patients with normal TPMT activity. TPMT activity was significantly higher in female patients with an Hb < 10g/dl (n = 250, mean TPMT 38.06 pmol/mg Hb/h) versus females with an Hb > 12g/dl (n = 2192, mean TPMT 32.46 pmol/mg Hb/h; p = < 0.0001). Similarly TPMT activity was significantly higher in male patients with an Hb < 10g/dl (n = 123, mean TPMT 38.14) versus males with an Hb > 12g/dl (n = 1901, mean TPMT 33.76; p = < 0.0001).
Conclusion TPMT activity in the wild-type range is lower in females than males, suggesting a post-translational influence on TPMT activity related to gender. Lower levels of SAM have been reported in females, which may explain this observation. Re-appraisal of the concordance between TPMT genotype and phenotype, adjusting for gender is therefore indicated. The finding of higher TPMT activity with anaemia may be due to a younger red cell population in this group. The difference in TPMT activities between patients with or without anaemia is clinically relevant, particularly where the TPMT activity is around the cut-off between intermediate (10–25 pmol/mg Hb/h) and normal (≥26 pmol/mg Hb/h) ranges. TPMT genotyping should be considered in such patients.
Disclosure of Interest None Declared
Karas-Kuzelicki, et al. Pharmacogenomics 2009. 10:1309–22.
Poirier, et al. Cancer epidemiology, biomarkers & prevention 2001. 10:649–655.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.